A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A QUADRIVALENT HUM

评估四价 HUM 免疫原性和安全性的 II 期研究

• 批准号: 8167119
• 负责人: ARDIS A MOE
• 金额: $ 0.53万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167119
• 关键词: Antibodies; CD4 Lymphocyte Count; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Grant; Human Papillomavirus; Institution; Phase; Recombinant Vaccines; Research; Research Personnel; Resources; Safety; Series; Source; United States National Institutes of Health; immunogenicity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the development of titers in each CD4+ cell count stratum of antibodies to HPV 6, 11, 16, and 18 above a level of type-specific seropositivity after the quadrivalent HPV recombinant vaccine series

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 确定四价HPV重组疫苗系列接种后，HPV 6、11、16和18型抗体的每个CD 4+细胞计数分层中滴度的发展高于型特异性血清阳性水平